Stanley L Hazen is affiliated with the Lerner Research Institute.He specializes in molecular medicine and preventive cardiology.He is a member of Department of Cellular and Molecular Medicine.
He holds the Jan Bleeksma Chair in Vascular Cell Biology and Atherosclerosis and the Leonard Krieger Chair in Preventive Cardiology.Hazen is named as co-inventor on pending and issued patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics, and has the right to receive royalty payment for inventions or discoveries related to cardiovascular diagnostics or therapeutics.He and colleagues have received patents for devices and tests that identify patients at increased risk for cardiovascular disease and for diagnosing asthma and treating inflammation and associated complications.He also is an elected fellow of the American Association for the Advancement of Science.He received his MD from the Washington University School of Medicine and completed his residency in internal medicine at Barnes-Jewish Hospital in St. Louis, where he also completed a fellowship in endocrinology.His earlier work has led to TMAO testing now being in clinical use around the world to measure cardiovascular disease risk.
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
Department of Cellular and Molecular Medicine
Some bacteria found in both mouse and human guts turn choline into trimethylamine, or TMA. In the liver, TMA is transformed into an artery-clogging compound that study coauthor Stanley Hazen and his colleagues previously linked to atherosclerosis risk in humans . Now the researchers have discovered that a cholinelike compound could be used as a drug to block TMA production. A high-choline diet caused plaques to build up in the arteries of mice genetically predisposed to atherosclerosis. But treating these mice with DMB completely prevented this artery clogging, he says.
Dr. Stanley Hazen of the Cleveland Clinic and colleagues did a small but intense study in 18 volunteers - eight of them vegetarians or vegans, and 10 people who eat meat, eggs and dairy. They gave all 18 choline supplements - 500 mg twice a day. Platelets are are cell-like structures in the blood that help form blood clots. "What is clear from this study is if you increase the choline in your diet, the TMAO level goes up and that changes your platelet function," he told NBC News. Even after taking choline, their blood levels were much lower.
One month on a heavy red-meat diet increased plasma and urine TMAO levels more than twofold compared with either a diet high in white meat or in non-meat proteins . Conversely, swapping out red meat for white meat or non-meat protein reduced blood and urine TMAO back to baseline levels within 4 weeks, Stanley Hazen, MD, PhD, of Cleveland Clinic, and colleagues reported online in European Heart Journal. While observational studies have demonstrated an association of TMAO with cardiovascular risk and animal studies demonstrated benefits from reduced TMAO levels, proving an impact of intervention to reduce TMAO on hard clinical endpoints in humans would be hard to do, and very expensive, she told MedPage Today in an email. His group also showed that red meat reduced fractional renal excretion of TMAO while increasing the excretion of carnitine and two of its alternative metabolites . In a separate study in the Journal of Clinical Investigation, his team discovered that carnitine gets converted to TMAO in a two-step pathway.